7LJE image
Entry Detail
PDB ID:
7LJE
Title:
Discovery of Spirohydantoins as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-01-29
Release Date:
2021-03-17
Method Details:
Experimental Method:
Resolution:
2.61 Å
R-Value Free:
0.26
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Histone acetyltransferase p300
Chain IDs:A, B, C, D
Chain Length:348
Number of Molecules:4
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases.
Bioorg.Med.Chem.Lett. 39 127854 127854 (2021)
PMID: 33631370 DOI: 10.1016/j.bmcl.2021.127854

Abstact

p300 and CREB-binding protein (CBP) are essential for a multitude of cellular processes. Dysregulation of p300/CBP histone acetyltransferase activity is linked to a broad spectrum of human diseases including cancers. A novel drug-like spirohydantoin (21) has been discovered as a selective orally bioavailable inhibitor of p300/CBP histone acetyltransferase. Lead compound 21 is more potent than the first-in-class lead A-485 in both enzymatic and cellular assays and lacks the off-target inhibition of dopamine and serotonin transporters, that was observed with A-485.

Legend

Protein

Chemical

Disease

Primary Citation of related structures